The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort, on an annual basis, conceived to strengthen the education of medical professionals willing to devote their career to rare cancers. Despite being [more]
According to an analysis just published on American Cancer Society’s CA: A Cancer Journal for Clinicians, rare cancers account for almost a fifth of all new diagnoses, and up to over two thirds of all new diagnoses [more]
Rare cancers were among the topics discussed last month at the 3rd conference on European Reference Networks held in Vilnius, in Lithuania, where Dr Paolo Casali, from the Milan’s Istituto Nazionale dei Tumori illustrated the goals of the Joint [more]
Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo Casali, a leading expert, presents an update of the latest evidence on the best way to [more]
Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment.Thus, this Course will be first offered to clinical oncologists involved into the existing networks covering rare adult solid [more]
Will pathology services need a serious overhaul if they are to deliver the accuracy required for precision medicine? Two European initiatives are trying to build the case for change in this least visible of cancer [more]
No pathologist can be an expert in every type of cancer. But there is a lot that can be done to greatly improve the accuracy of diagnoses, particularly in rare cancers, as a recent European [more]
France’s relatively low profile on the European cancer stage belies a creative and innovative approach to research and care that other countries could learn from. Agnès Buzyn lifts the lid on how French cancer services [more]
Conducting clinical trials in people with rare cancers is not easy when the number in a small trial do not add up to convincing evidence. Now some researchers are pressing for a new approach–using Bayesian [more]
A campaign to tackle the particular problems posed by rare cancers was launched this summer. European Action Against Rare Cancers (www.rarecancers.eu) is determined to put this neglected set of diseases firmly on the European health [more]
The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict [more]